RMB Capital Management LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 50.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,359 shares of the biopharmaceutical company’s stock after selling 9,608 shares during the quarter. RMB Capital Management LLC’s holdings in Gilead Sciences were worth $720,000 at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of GILD. Macquarie Group Ltd. boosted its holdings in Gilead Sciences by 1.5% in the fourth quarter. Macquarie Group Ltd. now owns 399,336 shares of the biopharmaceutical company’s stock valued at $25,948,000 after purchasing an additional 5,806 shares during the last quarter. Baldwin Brothers Inc. MA boosted its holdings in Gilead Sciences by 63.3% in the first quarter. Baldwin Brothers Inc. MA now owns 351 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 136 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its holdings in Gilead Sciences by 159.1% in the first quarter. Patriot Financial Group Insurance Agency LLC now owns 2,472 shares of the biopharmaceutical company’s stock valued at $185,000 after purchasing an additional 1,518 shares during the last quarter. Nwam LLC boosted its holdings in Gilead Sciences by 12.1% in the first quarter. Nwam LLC now owns 17,226 shares of the biopharmaceutical company’s stock valued at $1,288,000 after purchasing an additional 1,864 shares during the last quarter. Finally, Country Club Trust Company n.a. purchased a new stake in Gilead Sciences in the first quarter valued at $224,000. 78.74% of the stock is currently owned by institutional investors.
GILD stock opened at $68.50 on Friday. The company has a market cap of $86.31 billion, a price-to-earnings ratio of -285.40, a PEG ratio of 2.21 and a beta of 0.65. The company has a current ratio of 2.33, a quick ratio of 2.23 and a debt-to-equity ratio of 1.22. Gilead Sciences, Inc. has a 12 month low of $60.89 and a 12 month high of $85.97. The firm has a 50-day moving average of $73.94 and a two-hundred day moving average of $73.97.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.11 EPS for the quarter, missing the Zacks’ consensus estimate of $1.57 by ($0.46). The business had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.24 billion. Gilead Sciences had a negative net margin of 1.16% and a positive return on equity of 33.59%. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 6.96 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.68 per share. The ex-dividend date of this dividend is Monday, September 14th. This represents a $2.72 annualized dividend and a yield of 3.97%. Gilead Sciences’s dividend payout ratio is currently 44.30%.
Several equities research analysts have recently issued reports on the stock. SVB Leerink reissued a “buy” rating and set a $95.00 target price on shares of Gilead Sciences in a research note on Friday, July 31st. BidaskClub lowered shares of Gilead Sciences from a “sell” rating to a “strong sell” rating in a research note on Friday, July 24th. Wells Fargo & Co lowered their target price on shares of Gilead Sciences from $87.00 to $76.00 and set an “equal weight” rating on the stock in a research note on Friday, July 31st. Piper Sandler lowered their target price on shares of Gilead Sciences from $90.00 to $85.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of Gilead Sciences in a research note on Friday, August 7th. Four research analysts have rated the stock with a sell rating, sixteen have given a hold rating and nine have issued a buy rating to the company. Gilead Sciences presently has an average rating of “Hold” and a consensus target price of $79.68.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.